Rubicon Research Limited (NSE:RUBICON)

Market Cap	285.49B
Revenue (ttm)	19.36B +46.6%
Net Income	2.88B +89.5%
EPS	17.56 +78.9%
Shares Out	165.53M
PE Ratio	98.19
Forward PE	73.90
Dividend	1.50 (0.09%)
Ex-Dividend Date	Aug 7, 2026

Volume	274,829
Open	1,774.70
Previous Close	1,760.60
Day's Range	1,701.00 - 1,776.00
52-Week Range	570.75 - 1,820.10
Beta	n/a
Analysts	Strong Buy
Price Target	1,897.50 (+10.02%)
Earnings Date	Aug 14, 2026

About Rubicon Research

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as Rubi...

• Industry: Pharmaceutical Preparations
• Founded: 1999
• Employees: 1,290
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: RUBICON

Financial Performance

In fiscal year 2026, Rubicon Research's revenue was 17.54 billion, an increase of 36.57% compared to the previous year's 12.84 billion. Earnings were 2.47 billion, an increase of 83.64%.

Analyst Summary

According to 2 analysts, the average rating for RUBICON stock is "Strong Buy." The 12-month stock price target is ₹1,898, which is an increase of 10.02% from the latest price.

Price Target

₹1,898

(10.02% upside)

Analyst Consensus: Strong Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 22, 2026

Data Sources Report a data error